SCHEMBL7879490

SCHEMBL7879490

CNC(N)=NC(=O)c1cc2c(C)cccc2[nH]1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 6/20 0.48
PDGFRB P09619 2/20 0.48
KIT P10721 1/20 0.48
DAO P14920 1/20 0.44
DDO Q99489 1/20 0.44
SLC9A1 P19634 3/20 0.39
FGFR1 P11362 1/20 0.38
FGFR2 P21802 1/20 0.38
FGFR3 P22607 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
PARP14 Q460N5 1/20 0.38
DRD2 P14416 1/20 0.38
DRD3 P35462 1/20 0.38
HTR7 P34969 1/20 0.36
HTR2B P41595 1/20 0.36
HRH4 Q9H3N8 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
RCE1 Q9Y256 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7873714 0.99 FLT3 (0.47) FLT3PDGFRBKITDAODDO
SCHEMBL7884602 0.95 SLC9A1 (0.46) FLT3PDGFRBKITDAODDO
SCHEMBL7881376 0.86 HRH4 (0.50) FLT3PDGFRBKITHTR7HTR2B
SCHEMBL7884654 0.86 HRH4 (0.48) FLT3PDGFRBKITDAODDO
Hydrochloric Acid SCHEMBL7873302 0.85 HRH4 (0.49) FLT3PDGFRBKITHTR7HTR2B
SCHEMBL7881411 0.85 HRH4 (0.49) FLT3DAOSLC9A1DRD2DRD3
Hydrochloric Acid SCHEMBL7881212 0.85 HRH4 (0.47) FLT3PDGFRBKITDAODDO
Hydrochloric Acid SCHEMBL7882140 0.84 HRH4 (0.48) FLT3DAOSLC9A1DRD2DRD3
Hydrochloric Acid SCHEMBL7882177 0.84 HRH4 (0.48) FLT3DAODDOSLC9A1HTR7
SCHEMBL7882081 0.84 KIF11 (0.38) FLT3PDGFRBKITSLC9A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6169107-B1 USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS SUMITOMO PHARMACEUTICAL CO., LTD. (JP) 2001-01-02 US claimed
CN-1051301-C Indoloylguanidine derivatives SUMITOMO PHARMA (JP) 2000-04-12 CN claimed
EP-0622356-B1 Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange SUMITOMO PHARMA (JP) 1998-07-01 EP claimed
US-6248772-B1 HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2001-06-19 US disclosed
US-6169107-B1 USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS SUMITOMO PHARMACEUTICAL CO., LTD. (JP) 2001-01-02 US disclosed
EP-0622356-B1 Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange SUMITOMO PHARMA (JP) 1998-07-01 EP disclosed
CN-1136038-A Indoloylguanidine derivatives SUMITOMO PHARMACEUTICS K K (JP) 1996-11-20 CN disclosed
EP-0708091-A2 Indoloylguanidine derivatives SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1996-04-24 EP disclosed
CN-1106800-A Indoloylguanidine derivatives SUMITOMO PHARMA (JP) 1995-08-16 CN disclosed
EP-0622356-A1 Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1994-11-02 EP disclosed